The Waikar Lab’s overall goal is to improve the lives of our patients suffering from kidney disease through patient-oriented research. We use a highly collaborative and interdisciplinary approach to perform observational studies, biomarker discovery/validation, clinical trials, and implementation research. Our research projects are purposefully wide ranging and address areas of importance to patient care. Major current projects include the NIH Kidney Precision Medicine Project and research into novel biomarkers and therapeutic targets in AKI and CKD. Other ongoing studies include renal functional reserve; randomized controlled trials to improve the safety of hemodialysis and hemofiltration; optimal diagnostic testing in AKI and CKD; and optimizing care delivery in CKD and AKI.

Five selected publications:

1. Waikar SS et al. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. JAMA Internal Medicine, 2019. PMID: 30830167
2. Leaf D et al. Iron, hepcidin, and death in human AKI. Journal of American Society of Nephrology, 2019. PMID: 30737269
3. Waikar SS et al. Biological variability of estimated GFR and albuminuria in CKD. American Journal of Kidney Disease, 2018. PMID: 30031564
4. Mendu ML et al. The usefulness of diagnostic testing in the initial evaluation of chronic kidney disease. JAMA Internal Medicine, 2015. PMID: 25730699
5. McMahon GM et al. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Internal Medicine, 2013. PMID: 24000014